Editors at Insights in Biology and Medicine (IBM) safeguard scientific quality, fairness, and transparency. Decisions must be evidence-based, free from commercial influence, and consistent across submissions. Editors steward timely, constructive peer review while upholding ethical and legal standards.

  • Core values Integrity · Transparency · Equity · Rigor · Reproducibility
  • Review model Double-blind for research content; editorial screening for all submissions
  • Access Gold Open Access (CC BY 4.0)

1) Editorial Roles & Responsibilities

Editor-in-Chief (EiC)
  • Sets editorial policy; ensures consistency with ethics and legal standards.
  • Oversees appointments, training, and performance of Section Editors.
  • Handles escalations, complex ethics cases, appeals, and retraction decisions.
Section/Associate Editors
  • Conduct scope/quality triage; recruit qualified reviewers; synthesize reports.
  • Issue decisions (accept/minor/major/reject) with clear, actionable reasoning.
  • Verify ethics approvals, data/code availability, and image integrity flags.
Guest Editors (Special Issues)
  • Follow IBM standards; declare conflicts; avoid handling their own submissions.
  • Coordinate timelines; ensure reviewer diversity; avoid coercive citations.
Managing/Editorial Office
  • Operational QA (metadata, checklists, plagiarism screening).
  • Timeline monitoring; conflict-of-interest (COI) checks; communication templates.
  • Post-decision workflows (production handoff, Crossref deposit readiness).

2) Initial Triage (Days 0–7)

  1. Scope & fit: Aligns with Aims & Scope; novelty/advance beyond literature.
  2. Reporting basics: Abstract/keywords complete; ethics approvals where applicable; trial registration if required.
  3. Integrity checks: Plagiarism/similarity, figure forensics (splices, contrast), data/code statements present.
  4. Technical readiness: Anonymization for double-blind; figures and tables usable for review.
  5. Decision: Send to review or desk reject with constructive guidance.
Target time to first decision (with/without review) is within 28–35 days depending on complexity.

3) Reviewer Selection & Management

  • Expertise: Choose reviewers with methodological and subject expertise; avoid author-suggested reviewers with non-institutional emails.
  • Diversity & balance: Geographic, career-stage, and gender diversity; avoid clique effects.
  • COI screening: Exclude recent coauthors (last 3–5 years), same department, collaborators on grants, or personal relationships.
  • Blinding: Preserve double-blind; strip identifying file metadata before sending.
  • Timelines: Invite 3–4 reviewers aiming for 2–3 completed reports; set clear due dates and reminders.
Reviewer guidance note (send with invitation):

“Focus on methods, reproducibility, and clarity. Provide actionable feedback. Flag ethics/data concerns. Avoid coercive citation; declare conflicts.”

4) Decision Criteria & Letters

Base decisions on concordance of reviewer evidence and editorial appraisal. Provide a concise, respectful letter summarizing:

  1. Strengths and contributions.
  2. Major issues (methods, stats, controls, ethics, data availability).
  3. Specific, numbered action items for revision.
  4. Reporting standard(s) to apply (CONSORT/STROBE/PRISMA/ARRIVE/STARD).
Outcome When to use Notes
Accept Robust methods; all concerns resolved Ensure data/code links verified
Minor revision Limited clarifications; no new experiments needed Set ≤14-day target
Major revision Substantive issues; possible new analyses/controls Set 21–45-day target
Reject Out of scope, fatal flaws, or insufficient advance Offer transfer/scope guidance if appropriate

5) Ethics, COI & Sensitive Content

  • Human research: Confirm IRB approval, consent, and registration IDs where needed; check privacy/de-identification.
  • Animal research: IACUC/REC approvals; welfare reporting and humane endpoints.
  • Competing interests: Ensure disclosures from all authors; query ambiguous relationships (equity, consulting, patents).
  • Third-party materials: Verify permissions/licensing for figures, datasets, and instruments if proprietary.
  • AI tool use: Require AI-use statements; prohibit AI as author; watch for fabricated citations.
If serious concerns arise (fabrication, falsification, plagiarism, undisclosed COI), pause review and contact the editorial office to initiate an investigation workflow.

6) Research Integrity Checks

  • Similarity screening: Review similarity reports; distinguish overlap types (methods/common text vs. unattributed copying).
  • Image forensics: Look for duplicated bands/panels; require original uncropped images if flagged.
  • Statistics: Check internal consistency (n, p-values, CI, multiple testing corrections).
  • Data/code: Validate repository DOIs/accessions; if controlled-access, ensure clear request path.

7) Handling Revisions

  1. Ask for a point-by-point response mapping each reviewer/editor comment to changes.
  2. Request tracked changes plus a clean copy.
  3. Re-review by original reviewers for major changes; editor-only for minor clarifications.
  4. Ensure updated data/code links and ethical statements if new data added.

8) Appeals & Complaints

Authors may appeal decisions by providing a brief, evidence-based rationale addressing specific points. The EiC or an uninvolved senior editor evaluates appeals; original reviewers may be reconsulted or independent reviewers engaged. Complaints about process, bias, or conduct are logged and investigated by the editorial office.

9) Post-Publication Updates

  • Corrections: For material errors that do not invalidate conclusions; link bidirectionally to the Version of Record (VoR).
  • Retractions/Expressions of Concern: For serious integrity issues or unresolved concerns; follow transparent notices and metadata flags.
  • Commentaries/Replies: Facilitate scholarly discourse with fair tone and evidence-based arguments.

10) Special Issues & Collections

  • Pre-approve a scope, timeline, and guest editor team; document COIs.
  • Editorial independence: no guaranteed acceptance; same standards as regular issues.
  • Track submissions with a special-issue tag; maintain normal peer-review rigor.

11) Timelines & SLAs

Stage Target Escalation
Initial triage ≤ 7 days Escalate to Section Editor lead if overdue
Reviewer invitation to acceptance of invite ≤ 5 days Send alternate invites on day 3
Review completion 14–21 days Automated reminders; replace reviewer by day 21
First decision ≤ 35 days Notify EiC at day 40
Minor revision window ≤ 14 days Editor review only if minor
Major revision window 21–45 days Send back to reviewers

12) Communications & Tone

Communicate respectfully and concisely. Avoid prescriptive “must accept” language; instead, outline what evidence is needed to support claims. Encourage constructive framing and highlight paths to improve rigor and clarity.

Decision Letter Skeleton
Dear {Corresponding Author},

Thank you for submitting “{Title}” to Insights in Biology and Medicine.

Summary of strengths:
• {brief points}

To proceed, please address the following items:
1) Methods/controls/statistics: {details}
2) Data/code availability: {repository/DOI or controlled access route}
3) Reporting standards: {CONSORT/STROBE/PRISMA/ARRIVE/STARD elements}

Decision: {Minor/Major Revision}
Please provide a point-by-point response and a tracked-changes version.

Sincerely,
{Handling Editor}

13) Editorial Checklists

  • Scope fit and novelty assessed
  • Ethics approvals/consents verified
  • Data/Code statements with repository links present
  • Plagiarism and image checks completed
  • Blinding verified; author identifiers removed
  • Reviewer shortlist (diverse, qualified, non-conflicted)
  • All essential revisions completed and verified
  • Statistics and effect sizes consistent
  • Figures/tables accessible; alt text/legend quality
  • Data/code DOIs active; third-party permissions recorded
  • Final COI/funding statements complete

14) Confidentiality & Data Protection

  • Keep manuscripts and reviewer identities confidential.
  • Use the platform for communications; avoid personal email when possible.
  • Do not use or share unpublished data for personal advantage.

15) Handling Concerns & Misconduct

Route allegations through the editorial office. Maintain a documented timeline, preserve evidence, seek author responses, and (when appropriate) contact institutions or funders. Outcomes may include corrections, expressions of concern, or retractions. Keep communications neutral and factual.

16) Training & Continuous Improvement

  • Annual refresh on ethics, COI, and bias mitigation.
  • Shadowing and calibration exercises for new editors.
  • Periodic audits of decision consistency and turnaround metrics.
Plain-language note: Be fair, transparent, timely, and rigorous. Document decisions, verify ethics and data, and communicate actionable feedback.

Tools & Reference Signals

  • Reporting standards: CONSORT, STROBE, PRISMA, ARRIVE, STARD
  • Data/code repositories (discipline-appropriate) with DOIs/accessions
  • Good-practice guidance on corrections/retractions and handling concerns

Last updated: September 29, 2025 · Approx. word count: 1,850 · Content slug: editors-guidelines-ibm-2025-09